NRC Health reported FY 2025 revenue of USD 137.4 million (down 4% YoY) and operating income of USD 22.6 million (down 36% YoY), with an operating margin of 16%. FY 2025 net income was USD 11.6 million and diluted EPS was USD 0.50. Cash provided by operating activities was USD 26.5 million (down 24% YoY). Total Recurring Contract Value (TRCV), which the company describes as a leading indicator of revenue expectations, was USD 144.1 million (up 8% YoY); NRC Health said TRCV increased further to USD 152.0 million as of March 4, 2026. In corporate and business updates, NRC Health said TRCV has increased each quarter since Q4 2024 alongside improved revenue per associate and direct selling expenses, and highlighted senior management changes, new product development and marketing, the acquisition of its rounding tool, and sales force rebuilding. The company also cited efficiency measures, including operations automation and a lower-cost model for technology support and development. NRC Health said it expects revenue, operating margin, and operating cash flow to grow in 2026, supported by TRCV growth and a lower expense run rate.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRC - National Research Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-007002), on March 05, 2026, and is solely responsible for the information contained therein.